Editas Competitors
| EDIT Stock | USD 5.55 0.06 1.07% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Editas Medicine competition on your existing holdings.
Editas |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Editas Medicine's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Editas Medicine Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Editas Medicine and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Editas and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Editas Medicine does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Editas Stock performing well and Editas Medicine Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Editas Medicine's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BEAM | 3.79 | 0.13 | 0.00 | (0.06) | 4.31 | 8.32 | 35.34 | |||
| CRSP | 2.60 | (0.30) | 0.00 | (0.05) | 0.00 | 6.88 | 14.48 | |||
| CRBU | 3.27 | (0.31) | 0.00 | 0.56 | 0.00 | 9.14 | 41.79 | |||
| VERV | 3.89 | (0.98) | 0.00 | (0.18) | 0.00 | 7.36 | 56.42 | |||
| NTLA | 2.90 | (0.47) | 0.00 | (0.09) | 0.00 | 6.08 | 19.94 | |||
| PRME | 4.02 | (0.76) | 0.00 | (0.12) | 0.00 | 8.43 | 27.82 | |||
| VRTX | 0.89 | (0.21) | 0.00 | (0.22) | 0.00 | 1.70 | 5.49 | |||
| DNA | 4.16 | 0.00 | 0.00 | 0.00 | 0.00 | 7.09 | 25.50 | |||
| ALLO | 3.28 | 0.07 | 0.05 | 0.08 | 3.78 | 9.26 | 23.11 | |||
| SANA | 4.48 | 0.24 | 0.07 | 0.12 | 5.24 | 12.25 | 34.07 |
Cross Equities Net Income Analysis
Compare Editas Medicine and related stocks such as Beam TherapeuticsInc, Crispr Therapeutics, and Caribou Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAM | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (115.3 M) | (78.4 M) | (256.4 M) | (341.4 M) | (263.6 M) | (132.5 M) | (139.2 M) |
| CRSP | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (25.8 M) | (23.2 M) | (68.4 M) | (165 M) | 66.9 M | (348.9 M) | 377.7 M | (650.2 M) | (153.6 M) | (161.3 M) |
| CRBU | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (34.3 M) | (66.9 M) | (99.4 M) | (102.1 M) | (107.2 M) |
| VERV | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (45.5 M) | (118.6 M) | (157.4 M) | (200.1 M) | (190.1 M) |
| NTLA | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (12.4 M) | (31.6 M) | (67.5 M) | (85.3 M) | (92.7 M) | (125.6 M) | (259.7 M) | (490.2 M) | (481.2 M) | (457.1 M) |
| VRTX | (4.3 M) | 29.6 M | (107 M) | (445 M) | (738.6 M) | (558.1 M) | (112.1 M) | 263.5 M | 2.1 B | 1.2 B | 2.7 B | 2.3 B | 3.3 B | 3.6 B | 3.8 B |
| DNA | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (126.7 M) | (1.8 B) | (2.1 B) | (892.9 M) | (937.5 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (211.5 M) | (184.6 M) | (233.5 M) | (244.8 M) | (329.8 M) | (327.3 M) | (343.6 M) |
| SANA | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (278.6 M) | (344.2 M) | (266.4 M) | (283.3 M) | (297.4 M) |
Editas Medicine and related stocks such as Beam TherapeuticsInc, Crispr Therapeutics, and Caribou Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Editas Medicine financial statement analysis. It represents the amount of money remaining after all of Editas Medicine operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Editas Medicine Competitive Analysis
The better you understand Editas Medicine competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Editas Medicine's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Editas Medicine's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Editas Medicine Competition Performance Charts
Five steps to successful analysis of Editas Medicine Competition
Editas Medicine's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Editas Medicine in relation to its competition. Editas Medicine's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Editas Medicine in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Editas Medicine's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Editas Medicine, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Editas Medicine position
In addition to having Editas Medicine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Editas Medicine Correlation with its peers. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.